← Eichor
Study identifier: NCT05477459 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

LSD to Improve Cluster Headache Impact Trial

Condition: Chronic Cluster Headache  ·  Sponsor: Radboud University Medical Center

PhasePhase 2
Planned participants65
Who can joinAll sexes, 16 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to investigate the efficacy and safety of LSD 25μg every 3 days for 3 weeks versus placebo in the treatment of chronic cluster headache (cCH). It is a 3-week double-blind placebo-controlled intervention study, preceded by a 4-week baseline observation period and followed by a 5-week post-treatment observation period. Primary objective: to evaluate the efficacy of LSD 25μg every 3 days for 3 weeks in cCH. Additional objectives: * To evaluate the safety of LSD 25μg every 3 days for 3 weeks in cCH. * To explore the exposure-response relationship of 25μg LSD in cCH. * To explore cost-effectiveness of treatment with LSD in cCH. * To evaluate the efficacy of LSD on health-related quality of life.

This description comes directly from the study's public registry record.

Talk to the study team

Julia Jansen, MD  ·  +31 24 3658765  ·  julia.jansen@cwz.nl

Always discuss trial participation with your own doctor first.

Locations (2)

Leiden University Medical Center (LUMC)Leiden, NetherlandsRecruiting
Canisius-Wilhelmina Ziekenhuis (CWZ)Nijmegen, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05477459